Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfus…
What to know about VRTX
Vertex Pharmaceuticals Incorporated is a large Healthcare company with a solid overall financial profile. It scores well on health and risk, but valuation is worth keeping an eye on.
Should you consider VRTX?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
Vertex Pharmaceuticals Incorporated is a large-cap Healthcare company with a solid overall financial profile — it ranks in the top quarter of its Healthcare peers (3 of 59).
-
The business is both profitable and financially healthy — it keeps a good portion of what it earns and carries its debt comfortably.
-
The stock trades at a premium — investors are paying more per dollar of earnings than most S&P 500 companies. That's fine if strong growth justifies it, but leaves little room for disappointment.
-
Growth has been slower than most peers. That's not necessarily a dealbreaker, but it means the investment case rests more on current earnings than future expansion.
-
This stock pays no dividend — your return depends entirely on the share price rising over time.
-
Risk is relatively low — the stock tends to be less volatile than the broader market, which typically means a smoother ride during uncertain periods.
-
Analyst sentiment is broadly positive and short interest is low — professionals who cover this stock are mostly optimistic about its near-term prospects.
-
Overall, this is a well-rounded stock with multiple genuine strengths and few obvious weaknesses. It may suit investors looking for a reliable holding in the Healthcare space.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how VRTX compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 26.79 | Average |
| Forward P/E | 21.03 | Average |
| PEG Ratio | 1.70 | Above avg |
| Price to Sales | 9.38 | Below avg |
| Price to Book | 5.93 | Average |
| EV/EBITDA | 22.03 | Below avg |
| Earnings Yield | 3.73% | Average |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 54.39% | Above avg |
| Operating Margin | 38.13% | Top 25% |
| Net Profit Margin | 35.51% | Top 25% |
| Return on Equity | 24.20% | Above avg |
| Return on Invested Capital | 12.14% | Top 25% |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 7.80% | Average |
| Revenue Growth (3Y CAGR) | 10.35% | Top 25% |
| EPS Growth (YoY) | 61.40% | Top 25% |
| Free Cash Flow Growth | -426.56% | Below avg |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 3.02 | Top 25% |
| Debt to Equity | 0.10 | Top 25% |
| Interest Coverage | 350.11 | Top 25% |
| Altman Z-Score | 12.01 | Top 25% |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | — | N/A |
| Payout Ratio | 0.00% | Top 25% |
| Dividend Growth (5Y) | — | N/A |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 3.24% | Average |
| OCF to Sales | 34.71% | Top 25% |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 0.31 | Top 25% |
| Volatility (30-Day) | 24.93% | Above avg |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 2.00% | Top 25% |
| Avg. Analyst Rating | 1.61 | Top 25% |
| Target Upside % | 21.49% | Above avg |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 114.63B | Top 25% |
How does VRTX compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to VRTX — based on their financial profile.